Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Tarlatamab-dlle (Imdelltra) is a bispecific T-cell engager immunotherapy that targets delta-like ligand 3 (DLL3) and CD3, indicated for adult patients with extensive stage small cell lung cancer who have shown disease progression following or during platinum-based chemotherapy treatments.
• The information provided was derived from one document of the type 'Randomized Controlled Trials'.
• The study enrolled 220 patients who had previously undergone a median of two lines of treatment for small-cell lung cancer. These individuals represent a subgroup with more advanced disease stages and presumably higher burden of illness due to progression after platinum-based therapies.
• Patients were administered tarlatamab intravenously every 2 weeks at doses either 10 mg or 100 mg. Adverse events included cytokine release syndrome, decreased appetite, and pyrexia; however no new safety signals were identified suggesting manageable safety profile.
• In terms of effectiveness, the objective response rate was reported at 40% for the group receiving a dose level of 10-mg and at around about third in those receiving dosage levels up to ten times as high. Duration response lasted six months in over half responding patients indicating sustained benefit majority cases.
• Without comparisons to other drugs within this abstract it's difficult directly compare Imdelltra's safety efficacy other treatments ES-SCLC but outcomes suggest beneficial balance between efficacy manageable safety profiles challenging-to-treat patient population especially when given lower dosage level.